CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice

Pei, Ke-Ling; Yuan, Yi; Qin, San‐Hai; Wang, Yan; Zhou, Lixin; Zhang, Hou-Li; Qu, Xian‐Jun; Cui, Shu‐Xiang

doi:10.1007/s00280-011-1799-1

Cited by 8 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It constitutes a transcriptional target of RAS signaling pathways. ANPEP inhibitors have been reported to be effective anticancer agents (73). It is noteworthy that ANPEP has been proposed as a novel prognostic biomarker for patients with pancreatic cancer (74).…”

Section: Resultsmentioning

confidence: 99%

Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer?

Garmpis

Damaskos

Dimitroulis

et al. 2022

In Vivo

View full text Add to dashboard Cite

Pancreatic cancer is one of the most fatal malignancies, and therefore, new strategies, which aim at the improvement of the prognosis of this lethal disease, are needed. Many clinical trials have failed to improve overall survival. Nowadays, research is focused on advances provided by novel potential targets to efficiently enhance life expectancy. Cannabinoids, the active components of Cannabis sativa L., and their derivatives, have been reported as palliative adjuvants to conventional chemotherapeutic regimens. Cannabinoid effects are known to be mediated through the activation of cannabinoid receptors. To date, two cannabinoid receptors, cannabinoid receptor 1 and 2, have been cloned and identified from mammalian tissues. Cannabinoids exert a remarkable antitumoral effect on 543 This article is freely accessible online.

show abstract

Section: Resultsmentioning

confidence: 99%

Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer?

Garmpis

Damaskos

Dimitroulis

et al. 2022

In Vivo

View full text Add to dashboard Cite

show abstract

Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists

et al. 2013

View full text Add to dashboard Cite

The pancreatic adenocarcinoma cell line Panc1 was treated with cannabinoid receptor ligands (arachidonylcyclopropylamide or GW405833) in order to elucidate the molecular mechanism of their anticancer effect. A proteomic approach was used to analyze the protein and phosphoprotein profiles. Western blot and functional data mining were also employed in order to validate results, classify proteins, and explore their potential relationships. We demonstrated that the two cannabinoids act through a widely common mechanism involving up- and down-regulation of proteins related to energetic metabolism and cell growth regulation. Overall, the results reported might contribute to the development of a therapy based on cannabinoids for pancreatic adenocarcinoma.

show abstract

Cannabis and Cancer

Ross

2023

Plant-Based Therapeutics, Volume 1

View full text Add to dashboard Cite

CIP-13F, a novel aminopeptidase N (APN/CD13) inhibitor, inhibits Lewis lung carcinoma growth and metastasis in mice

Abstract: Our results showed that CIP-13F effectively inhibited LLC growth and pulmonary metastasis in mice and suggested that CIP-13F is a potential drug for the treatment for cancers with positive APN/CD13 expression.

Cited by 8 publications

References 33 publications

Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer?

Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer?

Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists

Cannabis and Cancer

Contact Info

Product

Resources

About